产品简要
公司名称 :
ACROBiosystems
产品类型 :
ELISA/assay
产品名称 :
ELISA Assay Kit for Anti-HER-2 h-mAb in Monkey Serum
目录 :
EHC-V1
规格 :
480试验
价格 :
1133美元
更多信息或购买 :
ACROBiosystems 产品网页
产品信息
公司名称 :
ACROBiosystems
产品类型 :
Kits
目录 :
EHC-V1
产品名称 :
ELISA Assay Kit for Anti-HER-2 h-mAb in Monkey Serum
规格 :
480试验
价格 :
1133美元
规格&价格 :
$1133/480tests
靶标 :
Her2
宿主物种 :
Monkey
研究 :
For Research Use Only
配方 :
想要获得更多细节请与我们联系信息
重组 :
See Certificate of Analysis for details of reconstitution instruction and specific concentration.
储存 :
Upon receipt, please store all items at -20℃. After reconstitution, the stock solution should be kept at -80℃. It is recommended not to freeze thaw more than 3 times. This product is stable after storage at: Room temperature (RT) for 1 month in lyophilized state; -20℃ for 1 year in lyophilized state; -80℃ for 4 months under sterile conditions after reconstitution.
背景 :
How a therapeutic antibody is metabolized in the body is pertinently relevant to its efficacy. Therefore, pharmacokinetics study is an important part of the drug development. HER-2 is probably the most targeted molecule in today’s pharmaceutical industry, thanking to the clinical success of Herceptin®. Many investigational anti-HER-2 mAbs are being developed. There is a growing need for a standard assay that can be used to facilitate the study of their pharmacokinetics.
更多信息或购买 :
ACROBiosystems 产品网页
公司信息
ACROBiosystems
1 Innovation Way Newark, DE 19711, USA
order@acrobiosystems.com
http://www.acrobiosystems.com
1-800-810-0816
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.

Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.

As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.

We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.